<DOC>
	<DOCNO>NCT00876694</DOCNO>
	<brief_summary>This study design collect long term safety data indacaterol ( 300 µg o.d . ) Japanese patient moderate severe COPD . Data study use registration indacaterol Japan .</brief_summary>
	<brief_title>Confirmatory Study Indacaterol Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . Diagnosis COPD ( moderatetosevere classify Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines ) : Smoking history least 20 packyears Postbronchodilator FEV1 &lt; 80 % ≥30 % predict normal value Postbronchodilator FEV1/FVC ( force vital capacity ) &lt; 70 % 1 . Patients hospitalize COPD exacerbation 6 week prior Visit 1 runin period 2 . Patients respiratory tract infection within 6 week prior Visit 1 3 . Patients concomitant pulmonary disease 4 . Patients history asthma 5 . Patients diabetes Type I uncontrolled diabetes Type II 6 . Any patient lung cancer history lung cancer 7 . Patients history certain cardiovascular comorbid condition 8 . Patients expose indacaterol previously . ( Except patient enrol Study CQAB149B1302 ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>COPD , Chronic Obstructive Pulmonary Disease , Indacaterol , long act β2-agonist</keyword>
</DOC>